



For settlement questions, or to get the claim process started, contact Janice Hart at (800) 729-5998 or email jhart@nationalequity.com

Remicade Antitrust Settlement

In re Remicade Antitrust Litigation, No. 2:17-cv-04326-KSM



Funds Amount: \$25M

Purchase Dates: April 5, 2016 – February 28, 2022

Filing Deadline: November 30, 2022

ELIGIBILITY:

All person and entities in the United States who indirectly purchased, paid and/or provided reimbursement for some of all of the purchase of Defendants' infliximab (Remicade) from April 5, 2016 through February 28, 2022. Cities, Towns, and Municipalities with self-funded prescription drug plans are eligible for this settlement.

SUMMARY:

A proposed \$25,000,000 Settlement has been reached in a class action lawsuit on behalf of consumers and third-party payors regarding the prescription drug Remicade. The class action lawsuit (In re Remicade Antitrust Litigation, No. 2:17-cv-04326-KSM) claims that Defendants Johnson & Johnson and Janssen Biotech, Inc. violated federal and state antitrust and consumer-protection laws by taking action to block competition by new entrants in the infliximab market.